Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.32 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | THRA | P10827 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31268924 | 0.90 | TLR7 (0.35) | KDM4ETLR7HRH4MAOAHRH3 | |
| SCHEMBL30984070 | 0.89 | TLR7 (0.34) | KDM4ETLR7HRH4CXCR1MAOA | |
| SCHEMBL30983783 | 0.86 | PDE2A (0.39) | KDM4EDRD2HRH4 | |
| SCHEMBL31268765 | 0.85 | TLR7 (0.37) | KDM4ETLR7HRH4MAOA | |
| Hydrochloric Acid SCHEMBL30983898 | 0.85 | PDE2A (0.39) | KDM4EDRD2HRH4 | |
| SCHEMBL31269450 | 0.83 | TLR7 (0.34) | TLR7HRH4MAOAHRH3IGF1R | |
| SCHEMBL31268985 | 0.83 | TLR7 (0.34) | KDM4ETLR7CXCR1MAOAHRH3 | |
| SCHEMBL31269220 | 0.82 | TLR7 (0.38) | KDM4ETLR7CXCR1MAOAPDK2 | |
| SCHEMBL31269155 | 0.80 | TLR7 (0.34) | DRD2TLR7PDK2 | |
| SCHEMBL31269005 | 0.80 | PDE2A (0.35) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |